Divergent roles for CD4+ T cells in the priming and effector/memory phases of adoptive immunotherapy.
about
Adoptive T cell therapy for cancer in the clinicInduction of protective and therapeutic antitumor immunity by a DNA vaccine with a glioma antigen, SOX6.Autologous MUC1-specific Th1 effector cell immunotherapy induces differential levels of systemic TReg cell subpopulations that result in increased ovarian cancer patient survival.Depletion of tumor-induced Treg prior to reconstitution rescues enhanced priming of tumor-specific, therapeutic effector T cells in lymphopenic hostsIn Vivo Murine-Matured Human CD3+ Cells as a Preclinical Model for T Cell-Based Immunotherapies.Bystander activation and anti-tumor effects of CD8+ T cells following Interleukin-2 based immunotherapy is independent of CD4+ T cell help.Bystander killing of cancer requires the cooperation of CD4(+) and CD8(+) T cells during the effector phase.Profound tumor-specific Th2 bias in patients with malignant glioma.Tumor-specific CD4+ T cells maintain effector and memory tumor-specific CD8+ T cells.Cancer immunotherapy: the role regulatory T cells play and what can be done to overcome their inhibitory effects.Tumor-derived autophagosome vaccine: induction of cross-protective immune responses against short-lived proteins through a p62-dependent mechanism.Prognostic significance of plasma interleukin-6/-8 in pancreatic cancer patients receiving chemoimmunotherapy.Multispectral imaging of formalin-fixed tissue predicts ability to generate tumor-infiltrating lymphocytes from melanoma.Immunotherapy for melanoma: the good, the bad, and the future.Intradermal NKT cell activation during DNA priming in heterologous prime-boost vaccination enhances T cell responses and protection against LeishmaniaTumor-infiltrating T lymphocytes: friends or foes?Therapeutic T cells induce tumor-directed chemotaxis of innate immune cells through tumor-specific secretion of chemokines and stimulation of B16BL6 melanoma to secrete chemokinesIncreased frequency of suppressive regulatory T cells and T cell-mediated antigen loss results in murine melanoma recurrenceMultiple vaccinations: friend or foe.Partial CD4 depletion reduces regulatory T cells induced by multiple vaccinations and restores therapeutic efficacy.IL-4 suppresses very late antigen-4 expression which is required for therapeutic Th1 T-cell trafficking into tumors.Is antigen specificity the key to efficient adoptive T-cell therapy?Identification of pancreatic cancer-associated tumor antigen from HSP-enriched tumor lysate-pulsed human dendritic cells.Identification of Melanoma-reactive CD4+ T-Cell Subsets From Human Melanoma Draining Lymph Nodes.Successful cancer vaccine therapy for carcinoembryonic antigen (CEA)-expressing colon cancer using genetically modified dendritic cells that express CEA and T helper-type 1 cytokines in CEA transgenic mice.Mannan-modified adenovirus as a vaccine to induce antitumor immunity.CD4 T cell knockout does not protect against kidney injury and worsens cancer.IL-12 enhances the generation of tumour antigen-specific Th1 CD4 T cells during ex vivo expansion.CTLA4-CD28 chimera gene modification of T cells enhances the therapeutic efficacy of donor lymphocyte infusion for hematological malignancy.Polyfunctional response by ImmTAC (IMCgp100) redirected CD8+ and CD4+ T cells.A novel strategy for tumour therapy combining cell apoptosis and active immunity induced by caspy2, a zebrafish caspase.Effects of zinc sulfate supplementation on cell-mediated immune response in head and neck cancer patients treated with radiation therapy.NK and CD8+ T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation.Enhancement of antitumour immunity by a novel chemotactic antigen DNA vaccine encoding chemokines and multiepitopes of prostate-tumour-associated antigens.Transfer of Allogeneic CD4+ T Cells Rescues CD8+ T Cells in Anti-PD-L1-Resistant Tumors Leading to Tumor Eradication.CCL19 (ELC) improves TH1-polarized immune responses and protective immunity in a murine Her2/neu DNA vaccination model.
P2860
Q24680405-7BA9F55B-8A66-4ED6-9D36-8F13141FB758Q33316774-DD952E60-42B4-4A1E-90CD-49DF94054F87Q33584997-B2F1C480-B5E8-44DC-A215-08CA741C8A9AQ33772479-47683A8A-E406-4AAC-B71E-088618DB561DQ33796950-9C1D54E1-3DB8-44B4-A75F-181D16C9C2CEQ34041058-B4A83197-A616-4EE1-AEAB-C7363FB01854Q34243372-766744D7-A286-437F-B6C1-32A97B31B375Q34491734-A495C888-ED38-4E2B-987E-B04AB0D933B9Q34823085-C1820C5B-11EF-4E3E-B6C4-B6C714CB43F4Q35033249-B5162FCC-D8D7-45F8-85AC-4724A7F500D3Q35816796-52C81E8B-1598-4EE6-8CB9-6678C3810476Q36168088-43938874-4B76-4FB5-ACC3-A6C8E8F51F93Q36198732-DDC7C749-BBA1-4866-8F95-DDF215BD9A37Q36223644-F1E7FB6B-C00A-47DE-9A59-E8E321CC5E12Q36251325-A2EC741D-8B41-4541-84E5-82B609A1CFB7Q36381918-966A3739-B21F-43B5-A58B-155A48308FAEQ36389337-DB9DF0AF-5260-43FD-A90F-7AF89CB5B61CQ36555546-8F7FBBFB-87AA-4339-B26B-84AD5040A8ADQ36734688-489E4742-FFAE-4F4D-A0F8-738AAD9FEA72Q37442739-926878F8-0F4D-434E-8A5A-22ABE421F478Q37485130-CACA4B21-D600-4320-9EB1-F618A61FEE6AQ37861214-ACF293E6-6929-4551-814F-FE30566D9538Q38437145-E7D1D889-BD47-41E9-9247-8F5DAFBBEB35Q38814049-09726C4A-F643-4980-A767-D4591B385981Q40209951-885FAB9B-28AF-4072-B786-EE9FD60FFB0DQ40243921-B212CBBB-2D55-4EAC-AAB1-7E7C1E34E7A1Q40260014-AAE24554-BF27-40DA-ACF9-41C2A3A238A5Q40596665-AA9F4A44-16DA-4209-8D48-9DA9A6BFEB09Q41480472-FFEE6906-3FF5-41DD-AD9B-445348E90418Q42371124-6A46FF98-6A1D-4574-B4E4-15CB8B96F943Q43782686-BCDD4408-CD6E-4768-8EB9-614176AE8C15Q44262245-3EBC8FB8-6FB1-4693-83A1-1215B67B3B4BQ45873342-9736192A-7F2A-4AB9-A0CE-D8B8D58717CBQ46942457-CB99414C-B3C2-45DD-8070-D2072F98229CQ50957786-12562046-C7F5-4E7E-A6F3-83AB8C12F648Q52890329-BAA644AD-1C93-49CE-99F5-934EE7B1F38E
P2860
Divergent roles for CD4+ T cells in the priming and effector/memory phases of adoptive immunotherapy.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh
2000年學術文章
@zh-hant
name
Divergent roles for CD4+ T cel ...... ses of adoptive immunotherapy.
@en
type
label
Divergent roles for CD4+ T cel ...... ses of adoptive immunotherapy.
@en
prefLabel
Divergent roles for CD4+ T cel ...... ses of adoptive immunotherapy.
@en
P2093
P1476
Divergent roles for CD4+ T cel ...... ses of adoptive immunotherapy.
@en
P2093
P304
P356
10.4049/JIMMUNOL.165.8.4246
P407
P577
2000-10-01T00:00:00Z